Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

作者：Damm Welk Christine^*; Siddiqi Faraz; Fischer Matthias; Hero Barbara; Narayanan Vignesh; Camidge David Ross; Harris Michael; Burke Amos; Lehrnbecher Thomas; Pulford Karen; Oschlies Ilske; Siebert Reiner; Turner Suzanne; Woessmann Wilhelm^*

来源：Journal of Cancer, 2016, 7(11): 1383-1387.

DOI：10.7150/jca.15238

• ALK-antibody titre
• NSCLC
• neuroblastoma
• lymphoma

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

• 出版日期2016